124 related articles for article (PubMed ID: 7473135)
1. Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes.
Lee M; Yang KH; Kaminski NE
J Pharmacol Exp Ther; 1995 Nov; 275(2):529-36. PubMed ID: 7473135
[TBL] [Abstract][Full Text] [Related]
2. Suppression of interleukin-2 by the putative endogenous cannabinoid 2-arachidonyl-glycerol is mediated through down-regulation of the nuclear factor of activated T cells.
Ouyang Y; Hwang SG; Han SH; Kaminski NE
Mol Pharmacol; 1998 Apr; 53(4):676-83. PubMed ID: 9547358
[TBL] [Abstract][Full Text] [Related]
3. Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism.
Kaminski NE; Koh WS; Yang KH; Lee M; Kessler FK
Biochem Pharmacol; 1994 Nov; 48(10):1899-908. PubMed ID: 7986201
[TBL] [Abstract][Full Text] [Related]
4. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW
Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of leukocyte function and interleukin-2 gene expression by 2-methylarachidonyl-(2'-fluoroethyl)amide, a stable congener of the endogenous cannabinoid receptor ligand anandamide.
Kaplan BL; Ouyang Y; Herring A; Yea SS; Razdan R; Kaminski NE
Toxicol Appl Pharmacol; 2005 Jun; 205(2):107-15. PubMed ID: 15893538
[TBL] [Abstract][Full Text] [Related]
6. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity.
Ben-Shabat S; Fride E; Sheskin T; Tamiri T; Rhee MH; Vogel Z; Bisogno T; De Petrocellis L; Di Marzo V; Mechoulam R
Eur J Pharmacol; 1998 Jul; 353(1):23-31. PubMed ID: 9721036
[TBL] [Abstract][Full Text] [Related]
7. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
Melck D; De Petrocellis L; Orlando P; Bisogno T; Laezza C; Bifulco M; Di Marzo V
Endocrinology; 2000 Jan; 141(1):118-26. PubMed ID: 10614630
[TBL] [Abstract][Full Text] [Related]
8. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses.
Bonhaus DW; Chang LK; Kwan J; Martin GR
J Pharmacol Exp Ther; 1998 Dec; 287(3):884-8. PubMed ID: 9864268
[TBL] [Abstract][Full Text] [Related]
9. 2-Arachidonoyl-glycerol suppresses interferon-gamma production in phorbol ester/ionomycin-activated mouse splenocytes independent of CB1 or CB2.
Kaplan BL; Ouyang Y; Rockwell CE; Rao GK; Kaminski NE
J Leukoc Biol; 2005 Jun; 77(6):966-74. PubMed ID: 15774549
[TBL] [Abstract][Full Text] [Related]
10. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.
Mechoulam R; Ben-Shabat S; Hanus L; Ligumsky M; Kaminski NE; Schatz AR; Gopher A; Almog S; Martin BR; Compton DR
Biochem Pharmacol; 1995 Jun; 50(1):83-90. PubMed ID: 7605349
[TBL] [Abstract][Full Text] [Related]
11. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling.
Paria BC; Das SK; Dey SK
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9460-4. PubMed ID: 7568154
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kappaB elements by cannabinol, a minimally CNS-active cannabinoid.
Herring AC; Koh WS; Kaminski NE
Biochem Pharmacol; 1998 Apr; 55(7):1013-23. PubMed ID: 9605425
[TBL] [Abstract][Full Text] [Related]
13. A COX-2 metabolite of the endogenous cannabinoid, 2-arachidonyl glycerol, mediates suppression of IL-2 secretion in activated Jurkat T cells.
Rockwell CE; Raman P; Kaplan BL; Kaminski NE
Biochem Pharmacol; 2008 Aug; 76(3):353-61. PubMed ID: 18571623
[TBL] [Abstract][Full Text] [Related]
14. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides.
Barg J; Fride E; Hanus L; Levy R; Matus-Leibovitch N; Heldman E; Bayewitch M; Mechoulam R; Vogel Z
Eur J Pharmacol; 1995 Dec; 287(2):145-52. PubMed ID: 8749028
[TBL] [Abstract][Full Text] [Related]
15. 2-arachidonyl-glycerol stimulates nitric oxide release from human immune and vascular tissues and invertebrate immunocytes by cannabinoid receptor 1.
Stefano GB; Bilfinger TV; Rialas CM; Deutsch DG
Pharmacol Res; 2000 Oct; 42(4):317-22. PubMed ID: 10987990
[TBL] [Abstract][Full Text] [Related]
16. Cyclic AMP is an essential factor in immune responses.
Koh WS; Yang KH; Kaminski NE
Biochem Biophys Res Commun; 1995 Jan; 206(2):703-9. PubMed ID: 7826390
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
[TBL] [Abstract][Full Text] [Related]
18. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
Priller J; Briley EM; Mansouri J; Devane WA; Mackie K; Felder CC
Mol Pharmacol; 1995 Aug; 48(2):288-92. PubMed ID: 7651362
[TBL] [Abstract][Full Text] [Related]
19. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase.
Vogel Z; Barg J; Levy R; Saya D; Heldman E; Mechoulam R
J Neurochem; 1993 Jul; 61(1):352-5. PubMed ID: 8515284
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.
Schatz AR; Lee M; Condie RB; Pulaski JT; Kaminski NE
Toxicol Appl Pharmacol; 1997 Feb; 142(2):278-87. PubMed ID: 9070350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
